医药行业周报：医药板块哪些子行业和公司预期一季度业绩好，重点关注创新药、力诺药包、浙江医药等

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2] Core Views - The report highlights strong growth expectations for several companies in the pharmaceutical sector, particularly in innovative drugs and specific sub-industries such as packaging and vitamins [5][12][13][21][25][30][37] Summary by Sections 1. Companies with Positive Q1 Performance Expectations - Linuo Packaging: The company is positioned well in the borosilicate molded bottle industry, with rapid expansion expected to enhance performance. The market demand for molded bottles is projected to reach 74 billion units by 2027, while current production capacity is only about 54 billion units [12] - Zhejiang Medicine: Anticipated high growth in Q1 2025 due to strong overseas demand for vitamins A and E, with vitamin E prices showing a significant increase [13][17] - Huayuan Bio: Expected to exceed Q1 performance expectations, driven by high prices for vitamin D3 and the rollout of new projects [21][24] - Yimaitong: As China's largest online professional physician platform, it has a solid user base and is leveraging AI to enhance its services [25][29] - Gushengtang: The company is integrating AI with traditional Chinese medicine, showing a steady increase in patient visits and average spending per visit [30][36] - Innovative Drugs: Focus on the volume of products entering the medical insurance list in Q1 2025, with several key drugs expected to perform well [37] 2. Market Performance Overview - The pharmaceutical sector index rose by 1.06% from March 3 to March 7, 2025, underperforming the CSI 300 index by 0.32%. Year-to-date, the sector index has increased by 2.19%, outperforming the CSI 300 by 1.95% [39][41] 3. Sector Valuation and Trading Volume - As of March 7, 2025, the overall valuation of the pharmaceutical sector is 31.2, reflecting a slight increase from the previous week [46] - The total trading volume for the pharmaceutical sector was 353.32 billion yuan, accounting for 4.2% of the total A-share market volume, with a decrease of 13.9% compared to the previous trading period [50][52]